Lipid Metabolism

Description

Lipid metabolism in the brain encompasses the synthesis, transport, modification, and degradation of cholesterol, phospholipids, sphingolipids, and fatty acids. The brain contains approximately 25% of the body's cholesterol despite being only 2% of body mass, and neurons depend entirely on astrocyte-derived cholesterol delivered via ApoE-containing lipoproteins. Lipid rafts -- cholesterol- and sphingolipid-enriched membrane microdomains -- serve as essential platforms for receptor signaling, synaptic vesicle cycling, and v-ATPase assembly.

In Alzheimer's disease, lipid metabolism dysfunction operates as a foundational upstream pathology. The APP fragment C99 functions as a cholesterol sensor at mitochondria-associated ER membranes (MAMs), and its accumulation due to gamma-secretase processing failure signals false cholesterol deficiency, driving aberrant lipid raft formation through ACAT1-mediated cholesterol esterification. ApoE4 carriers suffer compounded lipid dysfunction: the isoform's structural inability to properly accept lipids from ABCA1 transporters ("hypolipidation") starves endolysosomal membranes of essential lipids, destabilizing v-ATPase assembly. Meanwhile, lipid-droplet-accumulating microglia (LDAM) lose their phagocytic capacity and release inflammatory cytokines, creating a glial relay that converts astrocytes to the neurotoxic A1 phenotype.

Ceramide dysregulation represents another critical lipid axis: ceramides stabilize BACE1 (increasing amyloidogenic APP processing), activate PP2A to drive tau phosphorylation via GSK-3beta, and induce lysosomal membrane permeabilization. Lipidomic signatures have been detected in asymptomatic PSEN1 carriers as young as ages 6-12, suggesting lipid dysfunction is among the earliest detectable changes in AD pathogenesis.

Convergence Nodes

Endosomal Nexus -- Lipid raft disruption impairs receptor trafficking and endosomal sorting
APOE4 Hub -- APOE4 drives lipid transport failure at multiple levels
Compensatory Paradigm Nexus -- Lipid raft restructuring represents an allostatic adaptation that becomes pathological

Prize Entrants

Estela Area-Gomez -- Defined AD as fundamentally a lipid disorder through the C99 cholesterol sensor paradigm; demonstrated MAM hyperactivation and serum lipidomic signatures in presymptomatic carriers
Ari Rappoport -- Proposed neural cholesterol deficiency from failed astrocyte-to-neuron cholesterol transport as the primary AD driver
Brenda Aske -- Described the COIL hypothesis linking lipid-burdened LDAM microglia to glial relay neuroinflammation
Carina Clawson -- Identified ceramide-Abeta positive feedback loops and sphingolipid-mediated lysosomal permeabilization

External Scientists

David Holtzman -- ApoE isoform-specific effects on lipid metabolism and tau pathology
Hussein Yassine -- Brain DHA metabolism and ApoE4
Julia TCW -- iPSC-derived lipid metabolic profiling in ApoE genotypes
Norman Haughey -- Ceramide and sphingolipid biomarkers in AD

Key Open Questions

Is the primary lipid defect in AD a failure of transport (ApoE-mediated delivery), synthesis, or degradation?
Can lipid-restoring therapies (ABCA1 agonists, dietary omega-3 precursors) rescue autophagic function by stabilizing v-ATPase assembly?
How early in AD pathogenesis does lipidomic dysregulation begin, and can it serve as a preclinical biomarker?
Does the C99 cholesterol sensor model explain why BACE inhibitors failed clinically by paradoxically worsening lipid homeostasis?